Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19
NCT04346628
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
149
Enrollment
OTHER
Sponsor class
Conditions
Sars-CoV2
COVID-19
Interventions
DRUG:
Favipiravir
DRUG:
Placebo
OTHER:
Standard of care treatment
Sponsor
Stanford University